Patents by Inventor Erika Currier

Erika Currier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds with activity on muscarinic receptors
    Patent number: 7485651
    Abstract: Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: February 3, 2009
    Assignee: Acadia Pharmaceuticals, Inc.
    Inventors: Mark Brann, Terri Messier, Erika Currier, Kate Duggento, Tracy Spalding, Mikael Friberg, Niels Skjaerbaek
  • G-PROTEIN COUPLED RECEPTORS HIGH-THROUGHPUT FUNCTIONAL ASSAY
    Publication number: 20080280303
    Abstract: Disclosed herein are methods for enabling or improving functional assays of G-protein coupled receptors through the use of co-expression of helper genes. In some cases, chimeras linking the regulatory domain of the rap1B protein to the effector region of the ras oncogene are used in conduction with existing functional assays for cellular proliferation. Furthermore, overexpression of other genes can further augment the enabling properties of ras/rap chimeras.
    Type: Application
    Filed: May 12, 2008
    Publication date: November 13, 2008
    Inventors: Ethan S. Burstein, Fabrice Piu, Jian-Nong Ma, Jacques Weissman, David M. Weiner, Audra L. Scully, Norman Nash, Tracy Spalding, Erika Currier
  • COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS
    Publication number: 20080108618
    Abstract: Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 8, 2008
    Inventors: Mark Brann, Terri Messier, Erika Currier, Kate Duggento, Tracy Spalding, Mikael Friberg, Niels Skjaerbaek
  • G-protein coupled receptors high-throughput functional assay
    Publication number: 20050123964
    Abstract: Disclosed herein are methods for enabling or improving functional assays of G-protein coupled receptors through the use of co-expression of helper genes. In some cases, chimeras linking the regulatory domain of the rap1B protein to the effector region of the ras oncogene are used in conjuction with existing functional assays for cellular proliferation. Furthermore, overexpression of other genes can further augment the enabling properties of ras/rap chimeras.
    Type: Application
    Filed: November 2, 2004
    Publication date: June 9, 2005
    Inventors: Ethan Burstein, Fabrice Piu, Jian-Nong Ma, Jacques Weissman, David Weiner, Audra Scully, Norman Nash, Tracy Spalding, Erika Currier
  • Compounds with activity on muscarinic receptors
    Publication number: 20030144285
    Abstract: Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.
    Type: Application
    Filed: January 7, 2003
    Publication date: July 31, 2003
    Inventors: Mark Brann, Terri Messier, Erika Currier, Kate Duggento, Tracy Spalding, Mikael Friberg, Niels Skjaerbaek
  • Compounds with activity on muscarinic receptors
    Patent number: 6528529
    Abstract: Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.
    Type: Grant
    Filed: July 16, 1999
    Date of Patent: March 4, 2003
    Assignee: Acadia Pharmaceuticals Inc.
    Inventors: Mark Brann, Terri Messier, Erika Currier, Kate Duggento, Tracy Spalding, Mikael Friberg, Niels Skjaerbaek